Opdivo showed better in overall survival versus chemotherapy in advanced esophageal Cancer

Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy, according to results from Phase 3 ATTRACTION-3 trial to be featured in a Presidential Symposium during the European Society for Medical Oncology 2019 Annual Congress.

Read more

Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

Bristol-Myers squib’s Opdivo combined with Yervoy resulted in 52% of patients with being alive at five years, while 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free, the longest follow-up to date results for dual Immuno-Oncology (I-O) therapy in a Phase 3, randomized, controlled trial showed.

Read more

Three companies to evaluate the combination of Bayer’s kinase inhibitor Stivarga and BMS’s Opdivo

Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1

Read more